Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-ROBO1 CAR-T cells
- Development stage
- Preclinical
- Lead developer
- McMaster University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Anti-ROBO1 CAR-T cells are a second-generation chimeric antigen receptor (CAR) T-cell therapy designed to target the Roundabout guidance receptor 1 (ROBO1). ROBO1 is an axonal guidance protein that is aberrantly upregulated in malignant and treatment-refractory brain tumor initiating cells (BTICs), particularly in recurrent glioblastoma. Developed by researchers at McMaster University and the National Research Council Canada, these CAR-T cells utilize a single-domain antibody (nanobody) binding region to recognize ROBO1. In preclinical studies, the therapy has demonstrated potent anti-tumor activity, doubling median survival in patient-derived xenograft (PDX) models of recurrent glioblastoma and showing efficacy in models of lung-to-brain metastases and pediatric medulloblastoma.
- Other names
- ROBO1-targeted CAR T cellsROBO-1-targeted CAR T cellsROBO 1-targeted CAR T cellsanti-ROBO1 CAR T cellsanti-ROBO-1 CAR T cellsanti-ROBO 1 CAR T cells
02
Targets
ROBO1 (Roundabout guidance receptor 1)
Beyond the preview
Go deeper on anti-ROBO1 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-ROBO1 CAR-T cells.